Literature DB >> 18314445

Plasma apolipoprotein CI protects against mortality from infection in old age.

Jimmy F P Berbée1, Simon P Mooijaart, Anton J M de Craen, Louis M Havekes, Diana van Heemst, Patrick C N Rensen, Rudi G J Westendorp.   

Abstract

The high-density lipoprotein (HDL) constituent apolipoprotein CI (apoCI) protects mice against mortality in bacterial sepsis. We assessed whether high plasma apoCI levels protect against mortality from infection in humans. We determined plasma levels of apoCI, lipids, and C-reactive protein in 85-year-old participants of the prospective population-based Leiden 85-Plus Study (n = 561). Participants were followed for specific causes of death. High apoCI levels were associated with 40% reduced risk of mortality from infection (hazard ratio [HR], 0.60; 95% confidence interval [CI], 0.42-0.86; p =.005) for every increase of 1 standard deviation in apoCI level. A similar association was observed for high HDL cholesterol (HR, 0.65; 95% CI, 0.46-0.94; p =.022), but not for LDL cholesterol, triglycerides, and C-reactive protein levels. The association of apoCI was independent of HDL cholesterol, as multivariate analysis did not alter the association for apoCI (HR, 0.63; 95% CI, 0.44-0.90; p =.013), whereas for HDL cholesterol significance was lost. We conclude that high apoCI levels are associated with reduced mortality from infection, in line with experimental evidence in rodents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18314445     DOI: 10.1093/gerona/63.2.122

Source DB:  PubMed          Journal:  J Gerontol A Biol Sci Med Sci        ISSN: 1079-5006            Impact factor:   6.053


  8 in total

1.  Apolipoprotein CI enhances the biological response to LPS via the CD14/TLR4 pathway by LPS-binding elements in both its N- and C-terminal helix.

Authors:  Jimmy F P Berbée; Claudia P Coomans; Marit Westerterp; Johannes A Romijn; Louis M Havekes; Patrick C N Rensen
Journal:  J Lipid Res       Date:  2010-03-24       Impact factor: 5.922

2.  Constitutive inhibition of plasma CETP by apolipoprotein C1 is blunted in dyslipidemic patients with coronary artery disease.

Authors:  Xavier Pillois; Thomas Gautier; Benjamin Bouillet; Jean-Paul Pais de Barros; Aline Jeannin; Bruno Vergès; Jacques Bonnet; Laurent Lagrost
Journal:  J Lipid Res       Date:  2012-04-02       Impact factor: 5.922

3.  Changes in HDL-associated apolipoproteins relate to mortality in human sepsis and correlate to monocyte and platelet activation.

Authors:  Stefan Barlage; Carsten Gnewuch; Gerhard Liebisch; Zsuzsanna Wolf; Franz-Xaver Audebert; Thomas Glück; Dieter Fröhlich; Bernhard K Krämer; Gregor Rothe; Gerd Schmitz
Journal:  Intensive Care Med       Date:  2009-08-08       Impact factor: 17.440

Review 4.  Sepsis biomarkers: a review.

Authors:  Charalampos Pierrakos; Jean-Louis Vincent
Journal:  Crit Care       Date:  2010-02-09       Impact factor: 9.097

5.  Down-regulation of endothelial TLR4 signalling after apo A-I gene transfer contributes to improved survival in an experimental model of lipopolysaccharide-induced inflammation.

Authors:  Sophie Van Linthout; Frank Spillmann; Gallia Graiani; Kapka Miteva; Jun Peng; Eline Van Craeyveld; Marco Meloni; Markus Tölle; Felicitas Escher; Aysun Subasigüller; Wolfram Doehner; Federico Quaini; Bart De Geest; Heinz-Peter Schultheiss; Carsten Tschöpe
Journal:  J Mol Med (Berl)       Date:  2010-10-24       Impact factor: 4.599

6.  Assessment of ApoC1, LuzP6, C12orf75 and OCC-1 in cystic glioblastoma using MALDI-TOF mass spectrometry, immunohistochemistry and qRT-PCR.

Authors:  Petros Evangelou; Mathias Groll; Henry Oppermann; Frank Gaunitz; Christian Eisenlöffel; Wolf Müller; Klaus Eschrich; Anne Schänzer; Ulf Nestler
Journal:  Med Mol Morphol       Date:  2019-04-20       Impact factor: 2.309

Review 7.  Apolipoprotein C1: Its Pleiotropic Effects in Lipid Metabolism and Beyond.

Authors:  Elena V Fuior; Anca V Gafencu
Journal:  Int J Mol Sci       Date:  2019-11-26       Impact factor: 5.923

8.  Apolipoprotein C-I is an APOE genotype-dependent suppressor of glial activation.

Authors:  Eiron Cudaback; Xianwu Li; Yue Yang; Thomas Yoo; Kathleen S Montine; Suzanne Craft; Thomas J Montine; Christopher Dirk Keene
Journal:  J Neuroinflammation       Date:  2012-08-10       Impact factor: 8.322

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.